$2.90
2.36% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
US73730P1084
Symbol
PSTX
Sector
Industry

Poseida Therapeutics Inc Stock price

$2.90
+0.09 3.20% 1M
-0.18 5.84% 6M
-0.46 13.69% YTD
+0.46 18.61% 1Y
-4.71 61.89% 3Y
-12.45 81.11% 5Y
-12.45 81.11% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
-0.07 2.36%
ISIN
US73730P1084
Symbol
PSTX
Sector
Industry

Key metrics

Market capitalization $288.49m
Enterprise Value $134.33m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 639.67
EV/Sales (TTM) EV/Sales 1.52
P/S ratio (TTM) P/S ratio 3.26
P/B ratio (TTM) P/B ratio 4.74
Revenue growth (TTM) Revenue growth -43.55%
Revenue (TTM) Revenue $88.46m
EBIT (operating result TTM) EBIT $-118.46m
Free Cash Flow (TTM) Free Cash Flow $210.00k
Cash position $237.81m
EPS (TTM) EPS $-1.19
P/E forward negative
P/S forward 3.33
EV/Sales forward 1.55
Short interest 5.56%
Show more

Is Poseida Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Poseida Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Poseida Therapeutics Inc forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Poseida Therapeutics Inc forecast:

Buy
100%

Financial data from Poseida Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
88 88
44% 44%
100%
- Direct Costs 5.61 5.61
3% 3%
6%
83 83
45% 45%
94%
- Selling and Administrative Expenses 33 33
1% 1%
38%
- Research and Development Expense 162 162
15% 15%
184%
-113 -113
383% 383%
-128%
- Depreciation and Amortization 5.61 5.61
3% 3%
6%
EBIT (Operating Income) EBIT -118 -118
311% 311%
-134%
Net Profit -113 -113
286% 286%
-127%

In millions USD.

Don't miss a Thing! We will send you all news about Poseida Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Poseida Therapeutics Inc Stock News

Neutral
PRNewsWire
about 4 hours ago
Data showed a 91% ORR with P-BCMA-ALLO1 in an optimized lymphodepletion arm, including a 100% ORR in BCMA-naïve patients, and an 86% ORR in those who had received at least one prior BCMA- and/or GPRC5D-targeting treatment modality Differentiated P-BCMA-ALLO1 safety results with no dose-limiting toxicities, low rates of CRS and ICANS all Grade 2 or less and no graft vs. host disease or Parkinson...
Neutral
PRNewsWire
12 days ago
FDA evaluated RMAT application based on positive clinical data from ongoing Phase 1 study of P-BCMA-ALLO1; new clinical data from the study will be presented at the 21st International Myeloma Society Annual Meeting this month RMAT designation recognizes potential of P-BCMA-ALLO1 to address significant unmet needs of multiple myeloma patients and enables increased dialogue with FDA throughout th...
Positive
Seeking Alpha
18 days ago
Poseida Therapeutics shows promising early results in myeloma with their BCMA-directed allogeneic CAR T-cell therapy, achieving a 60% response rate in phase 1 trials. Financially stable with $30.5 million in cash, $207.3 million in short-term investments, and a $20 million milestone payment from Roche extending their cash runway. Strong partnerships with big pharma and deep cash reserves provid...
More Poseida Therapeutics Inc News

Company Profile

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded by Eric M. Ostertag in 2014 and is headquartered in San Diego, CA.

Head office United States
CEO Kristin Yarema
Employees 330
Founded 2014
Website www.poseida.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today